Bradykinesia News and Research

RSS
Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Nonmotor predictors of Parkinson’s dementia revealed

Nonmotor predictors of Parkinson’s dementia revealed

Brain network measures placebo effects in Parkinson's disease patients

Brain network measures placebo effects in Parkinson's disease patients

Low accuracy of clinical diagnosis for early Parkinson’s disease

Low accuracy of clinical diagnosis for early Parkinson’s disease

GLNT receives allowance of patent for Parkinson's disease monitoring technology

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Great Lakes NeuroTechnologies receives another patent for Parkinson’s disease monitoring technology

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Kinesia ProView™ launched to visualize motor symptom severity response to deep brain stimulation (DBS) in Parkinson’s patients

Parkinson's-related mutations may also affect vision

Parkinson's-related mutations may also affect vision

Intelligent algorithms for programming deep brain stimulation in Parkinson’s to be developed by Great Lakes NeuroTechnologies

Intelligent algorithms for programming deep brain stimulation in Parkinson’s to be developed by Great Lakes NeuroTechnologies

Parkinson’s assessment devices from Great Lakes NeuroTechnologies receive TGA approval

Parkinson’s assessment devices from Great Lakes NeuroTechnologies receive TGA approval

Bradykinesia is ‘context-specific’ in Parkinson’s

Bradykinesia is ‘context-specific’ in Parkinson’s

Bradykinesia in Parkinson’s disease: an interview with Dr. Joseph Giuffrida, President of Great Lakes NeuroTechnologies

Bradykinesia in Parkinson’s disease: an interview with Dr. Joseph Giuffrida, President of Great Lakes NeuroTechnologies

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Surprise result in caffeine trial for Parkinson’s patients

Surprise result in caffeine trial for Parkinson’s patients

Micrographia prevalent in Parkinson’s

Micrographia prevalent in Parkinson’s

UCB’s Neupro now available in U.S. pharmacies

UCB’s Neupro now available in U.S. pharmacies

Deep brain stimulation remains an effective treatment for Parkinson's

Deep brain stimulation remains an effective treatment for Parkinson's

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

European launch of technology for quantitative assessment of Parkinson’s disease symptoms from Great Lakes NeuroTechnologies

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies